What Is A UK Wholesale Dealer's Authorisation (WDA(H))?

UK Wholesale Dealer's Authorisation (WDA(H)) MHRA authorisation required for covered wholesale distribution of human medicines in the UK. The WDA(H) is the licence a legal entity needs to carry out wholesale distribution activity for human medicines that fall within UK regulations. It is issued by the Medicines and Healthcare products Regulatory Agency (MHRA) and ties the holder to regulatory requirements for premises, record-keeping, controlled distribution practices and staff responsibilities.

The WDA(H) is written to the legal entity and specific premises rather than an individual. A single company operating multiple warehouses needs a WDA(H) for each site that will carry out regulated wholesale activity unless those sites are explicitly covered by a single authorisation. Typical wholesale activities include receipt, storage, supply and dispatch of medicinal products to pharmacies, hospitals, wholesalers and some third parties. Activities like repackaging or relabelling may trigger additional conditions or require separate permissions.

What The Authorisation Covers

The licence authorises covered wholesale distribution of human medicines that are subject to the Human Medicines Regulations and MHRA oversight. It sets the scope of permitted activity, often listing types of products (e.g., prescription-only medicines) and specifying permitted operations such as storage, distribution and wholesale-to-wholesale transfers. The authorisation will also specify any limits or special conditions relating to controlled substances, temperature-controlled products or specific controlled distribution chains.

Why It Matters For Fulfillment Providers

Holding a WDA(H) is a legal requirement for many fulfilment providers that handle medicines. Without it, a 3PL or warehouse cannot legally accept, store or dispatch regulated human medicinal products on behalf of a merchant. This affects contract packaging, cold-chain fulfilment and returns handling. Carriers and marketplaces may also require evidence of a WDA(H) before allowing listings or logistics services for pharmaceutical goods.

Key Compliance Elements

• Responsible Person (RP): A named individual whose responsibilities include ensuring compliance with the terms of the WDA(H) and applicable regulations.
• Premises Standards: Physical controls and layout must support secure storage, segregation of recalled or quarantined stock, and, where needed, temperature management.
• Record-Keeping: Traceability from receipt to dispatch, batch records and supply chain provenance must be maintained for inspection.
• Good Distribution Practice (GDP): Written procedures and staff training are required to meet GDP principles for medicines distribution.

How The Application Process Works

Applications are submitted to the MHRA and require detailed information about the legal entity, premises, the Responsible Person, standard operating procedures and the types of medicines to be handled. Inspections are typically part of the assessment where MHRA assessors verify the premises, documentation and staff competence. Applicants must demonstrate that they can meet GDP requirements and that their systems control risks such as theft, contamination or cold-chain failure.

How It Varies By Operation

Smaller operations handling only over-the-counter products may face a lighter regulatory burden than full-scope dispensers of prescription medicines, but an authorisation is still required if activities fall within the wholesale distribution definition. Cold-chain operations add requirements for validated temperature control, monitoring and contingency plans. Businesses that also undertake manufacturing or repackaging should review whether additional MHRA licences are needed.

Practical Example For A 3PL

A third-party logistics provider that wants to store and ship temperature-sensitive prescription drugs for multiple clients must apply for a WDA(H) for the warehouse site. The application should identify an experienced Responsible Person, provide GDP-compliant SOPs for receipt, storage, returns and transport, and show temperature mapping and validation for cold rooms. During inspection, MHRA will check traceability, quarantine processes and staff training records. Contracts with clients should reference the WDA(H) conditions and any service-level obligations for temperature excursions or recalls.

Common Pitfalls

• Incorrect Scope: Assuming that a general business licence covers medicines distribution — many businesses need the specific WDA(H).
• Poor Documentation: Incomplete batch records or inadequate SOPs are frequent reasons for inspection findings.
• Inadequate Responsible Person Arrangements: Nominating an RP without authority or resource to enforce compliance creates regulatory risk.

In short, the UK Wholesale Dealer's Authorisation (WDA(H)) is the MHRA authorisation required for covered wholesale distribution of human medicines in the UK and is central to legal, safe and auditable fulfilment of medicinal products. Warehouses and fulfilment providers should plan applications around robust premises controls, a competent Responsible Person, GDP-aligned procedures and clear client contracts to avoid inspection findings and ensure uninterrupted operations.